China Oncology ›› 2023, Vol. 33 ›› Issue (5): 469-477.doi: 10.19401/j.cnki.1007-3639.2023.05.007
• Article • Previous Articles Next Articles
CHEN Lijun(), WANG Yichen, ZHENG Qiang, WANG Yue, JIN Yan, LI Yuan()
Received:
2022-10-17
Revised:
2023-03-21
Online:
2023-05-30
Published:
2023-06-16
Contact:
LI Yuan
CLC Number:
CHEN Lijun, WANG Yichen, ZHENG Qiang, WANG Yue, JIN Yan, LI Yuan. Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma[J]. China Oncology, 2023, 33(5): 469-477.
Tab. 1
Number of positive cases of ESCC under different cut-off for CPS or TPS using PD-L1 22C3, SP263 and 28-8 antibodies [n (%)]"
PD-L1 antibody clone | Positive case (n=78) | |||
---|---|---|---|---|
CPS≥10 | CPS≥1 | TPS≥10% | TPS≥1% | |
22C3 | 38 (48.7) | 68 (87.2) | 25 (32.1) | 41 (52.6) |
SP263 | 41 (52.6) | 73 (93.6) | 28 (35.9) | 48 (61.5) |
28-8 | 40 (51.3) | 70 (89.7) | 27 (34.6) | 43 (55.1) |
Tab. 2
Number of positive cases of ESCC under different cut-off for CPS or TPS using PD-L1 22C3, E1L3N XP, CST E1L3N, BP6099, MXR006 antibodies[n (%)]"
PD-L1 antibody clone | Positive case (n=68) | |||
---|---|---|---|---|
CPS≥10 | CPS≥1 | TPS≥10% | TPS≥1% | |
22C3 | 33 (48.4) | 62 (91.2) | 20 (29.3) | 43 (63.2) |
E1L3N XP | 29 (42.6) | 64 (94.1) | 17 (25.0) | 46 (67.6) |
CST E1L3N | 31 (45.6) | 63 (92.6) | 18 (26.5) | 57 (83.8) |
BP6099 | 22 (32.4) | 61 (89.7) | 16 (23.5) | 51 (75.0) |
MXR006 | 29 (42.6) | 62 (91.2) | 19 (27.9) | 48 (70.6) |
Tab. 3
Number of consistent cases in ESCC with CPS, TPS and IPS at cut-off value of 1 or 10 using PD-L1 22C3 and SP263, 28-8 antibody assays [n (%)]"
PD-L1 antibody clone | Concordant case (n=78) | |||
---|---|---|---|---|
CPS≥10 | CPS≥1 | TPS≥10% | TPS≥1% | |
22C3 vs SP263 | 69 (88.5) | 73 (93.6) | 73 (93.6) | 69 (88.5) |
22C3 vs 28-8 | 72 (92.3) | 76 (97.4) | 74 (94.9) | 68 (87.2) |
SP263 vs 28-8 | 67 (85.9) | 75 (96.2) | 75 (96.2) | 73 (93.6) |
Fig. 3
Comparison of interpretation results in ESCC using PD-L1 22C3 with four domestic clone number antibodies under three scoring systems A-C: Comparison of CPS, TPS and IPS interpretation results using PD-L1 22C3, E1L3N XP, CST E1L3N, BP6099 and MXR006 antibodies in each case. D: Distribution and median comparison of CPS, TPS and IPS interpretation results using PD-L1 22C3, E1L3N XP, CST E1L3N, BP6099 and MXR006 antibodies in 68 cases."
Tab. 4
Number of consistent cases in ESCC with CPS, TPS and IPS at cut-off value of 1 or 10 using PD-L1 22C3 and E1L3N XP, CST E1L3N, BP6099, MXR006 antibody assay [n (%)]"
PD-L1 antibody clone | Concordant case (n=68) | |||||
---|---|---|---|---|---|---|
CPS≥10 | CPS≥1 | TPS≥10% | TPS≥1% | IPS≥10% | IPS≥1% | |
22C3 vs E1L3N XP | 64 (94.1) | 66 (97.0) | 65 (95.6) | 65 (95.6) | 57 (83.8) | 47 (69.1) |
22C3 vs CST E1L3N | 64 (94.1) | 65 (95.6) | 64 (94.1) | 65 (95.6) | 52 (76.5) | 50 (73.5) |
22C3 vs BP6099 | 57 (83.8) | 63 (92.6) | 64 (94.1) | 63 (92.6) | 49 (72.0) | 57 (83.8) |
22C3 vs MXR006 | 60 (88.2) | 64 (94.1) | 65 (95.6) | 64 (94.1) | 50 (73.5) | 54 (79.4) |
E1L3N XP vs CST E1L3N | 62 (91.2) | 67 (98.5) | 65 (95.6) | 66 (97.0) | 57 (83.8) | 55 (80.9) |
E1L3N XP vs BP6099 | 51 (75.0) | 65 (95.6) | 65 (95.6) | 64 (94.1) | 56 (82.3) | 56 (82.3) |
E1L3N XP vs MXR006 | 60 (88.2) | 66 (97.0) | 66 (97.0) | 65 (95.6) | 55 (80.9) | 57 (83.8) |
CST E1L3N vs BP6099 | 59 (86.8) | 66 (97.0) | 66 (97.0) | 66 (97.0) | 61 (89.7) | 53 (77.9) |
CST E1L3N vs MXR006 | 60 (88.2) | 65 (95.6) | 67 (98.5) | 65 (95.6) | 60 (88.2) | 58 (85.3) |
BP6099 XP vs MXR006 | 61 (89.7) | 63 (92.6) | 65 (95.6) | 63 (92.6) | 57 (83.8) | 53 (77.9) |
[1] | 李琦, 李涛, 范羽, 等. PD-1/PD-L1在食管鳞状细胞癌中的表达及临床意义[J]. 肿瘤预防与治疗, 2018, 31(4)248-257 |
LI Q, LI T, FAN Y, et al. Expression of PD-1/PD-L1 in esophageal squamous cell carcinoma and its clinical significance[J]. J Cancer Control Treat, 2018, 31(4)248-257 | |
[2] | 王程浩, 韩泳涛. 2020年中国临床肿瘤学会《食管癌诊疗指南》解读[J]. 肿瘤预防与治疗, 2020, 33(4): 285-290. |
WANG C H, HAN Y T. Interpretation of the 2020 guidelines for the diagnosis and treatment of esophageal cancer by Chinese society of clinical oncology[J]. J Cancer Control Treat, 2020, 33(4): 285-290. | |
[3] |
SHAH M A, KOJIMA T, HOCHHAUSER D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]. JAMA Oncol, 2019, 5(4): 546-550.
doi: 10.1001/jamaoncol.2018.5441 pmid: 30570649 |
[4] |
KOJIMA T, SHAH M A, MURO K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148.
doi: 10.1200/JCO.20.01888 |
[5] |
HUANG Z L, JIN Y, CAI X, et al. Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer[J]. Thorac Cancer, 2022, 13(4): 523-532.
doi: 10.1111/tca.v13.4 |
[6] |
GUO W, WANG P, LI N, et al. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis[J]. Oncotarget, 2018, 9(17): 13920-13933.
doi: 10.18632/oncotarget.23810 pmid: 29568405 |
[7] |
BANG Y J, RUIZ E Y, VAN CUTSEM E, et al. Phase Ⅲ, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300[J]. Ann Oncol, 2018, 29(10): 2052-2060.
doi: 10.1093/annonc/mdy264 |
[8] |
MURO K, CHUNG H C, SHANKARAN V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2016, 17(6): 717-726.
doi: S1470-2045(16)00175-3 pmid: 27157491 |
[9] |
JANJIGIAN Y Y, BENDELL J, CALVO E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer[J]. J Clin Oncol, 2018, 36(28): 2836-2844.
doi: 10.1200/JCO.2017.76.6212 pmid: 30110194 |
[10] |
LEONE A G, PETRELLI F, GHIDINI A, et al. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score[J]. ESMO Open, 2022, 7(1): 100380.
doi: 10.1016/j.esmoop.2021.100380 |
[11] |
HIRSCH F R, MCELHINNY A, STANFORTH D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol, 2017, 12(2): 208-222.
doi: S1556-0864(16)33536-5 pmid: 27913228 |
[12] |
TSAO M S, KERR K M, KOCKX M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project[J]. J Thorac Oncol, 2018, 13(9): 1302-1311.
doi: S1556-0864(18)30626-9 pmid: 29800747 |
[13] | KRIGSFELD G S, ZERBA K, NOVOTNY J Jr, et al. A comparative study of the PD-L1 IHC 22C3 and 28-8 assays on lung cancer samples[J]. Int J Radiat Oncol, 2019, 104(1): 236-237. |
[14] |
WATANABE T, OKUDA K, MURASE T, et al. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma[J]. Oncotarget, 2018, 9(29): 20769-20780.
doi: 10.18632/oncotarget.25100 pmid: 29755688 |
[15] |
DE RUITER E J, MULDER F J, KOOMEN B M, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)[J]. Mod Pathol, 2021, 34(6): 1125-1132.
doi: 10.1038/s41379-020-0644-7 |
[16] | KRIGSFELD G S, PRINCE E, ZERBA K, et al. Analysis of real-world PD-L1 testing in patients with urothelial carcinoma[J]. J Clin Oncol, 2019, 37(7_suppl): 447. |
[17] |
KARNIK T, KIMLER B F, FAN F, et al. PD-L1 in breast cancer: comparative analysis of 3 different antibodies[J]. Hum Pathol, 2018, 72: 28-34.
doi: S0046-8177(17)30281-2 pmid: 28843709 |
[18] |
ADAM J, LE STANG N, ROUQUETTE I, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer[J]. Ann Oncol, 2018, 29(4): 953-958.
doi: S0923-7534(19)45464-1 pmid: 29351573 |
[19] |
BÜTTNER R, GOSNEY J R, SKOV B G, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer[J]. J Clin Oncol, 2017, 35(34): 3867-3876.
doi: 10.1200/JCO.2017.74.7642 pmid: 29053400 |
[20] |
UDALL M, RIZZO M, KENNY J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics[J]. Diagn Pathol, 2018, 13(1): 12.
doi: 10.1186/s13000-018-0689-9 pmid: 29426340 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd